Is Annexon, Inc. (ANNX) a Buy, Sell, or Hold?
Annexon, Inc.
NASDAQ:ANNX
$6.232 USD
$0.68 (12.29%)
- Volume
- 6.68M
- Average Volume
- 3.2M
- Market Capitalization
- $745.32M
- P/E Ratio
- -5.11
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $7.18
- Year Low
- $2.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $-0.01
- Current Ratio
- $6.35
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Douglas E. Love |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ANNX |
| CUSIP | 03589W102 |
| CIK | 0001528115 |
| Web | https://www.annexonbio.com |
| Phone | 650 822 5500 |
| Currency | USD |
| Employees | 96 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.12 |
| Payout Ratio | -0.01 |
| Current Ratio | 6.35 |
| Quick Ratio | 6.35 |
| Cash Ratio | 4.88 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.94 |
| Price / Cash Flow | -4.07 |
| Price / Book | 5.92 |
Price Target and Rating
| Average Stock Price Forecast | $7.00 |
| High Stock Price Forecast | $7.00 |
| Low Stock Price Forecast | $7.00 |
| Forecast Upside/Downside | -10.97% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.34 |
| Trailing P/E Ratio | -5.11 |
| PEG Ratio | 0.84 |
| P/E Growth | 0.84 |
| Net Income | $-206.69M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -101.19% |
| Return on Assets | -74.74% |
Financials Score
| AltmanZ Score | 0.21 |
| Piotroski Score | 1.00 |
| Working Capital | 192.33M |
| Total Assets | 262.89M |
| Ebit | -196.48M |
| Market Cap | 673.32M |
| Total Liabilities | 58.36M |
Poll Results
About Annexon, Inc. (NASDAQ:ANNX) Stock
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral scler ... osis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
2026-07-14 16:05:00
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting being held July 15–18, 2026 in Montréal, Québec, Canada.
Annexon: Perfect Complement To A Speculative Biotech Portfolio
2026-07-14 05:43:52
Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably tanruprubart for Guillain-Barré syndrome (GBS). Tanruprubart achieved highly significant Phase 3 results, with a 2.4-fold GBS-DS improvement versus placebo and strong safety, positioning it for standard-of-care status. Regulatory filings are underway: MAA was submitted to EMA, with FDA BLA planned for 2026, supported by ongoing FORWARD and real-world evidence studies.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-06-16 16:05:00
BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-06-09 10:42:15
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
2026-06-09 09:07:24
Annexon NASDAQ: ANNX executives used a Goldman Sachs Healthcare Conference session to outline the company's upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular degeneration.
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
2026-06-04 03:07:38
Annexon NASDAQ: ANNX executives outlined a series of expected clinical and regulatory updates across the company's complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin disease.
Annexon to Participate in Upcoming June Investor Conferences
2026-05-27 08:00:00
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following June investor conferences:
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-05-18 16:05:00
BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
Frequently Asked Questions
-
What is the current Annexon, Inc. (ANNX) stock price?
-
Annexon, Inc.(NASDAQ:ANNX) stock price is $6.232 in the last trading session. During the trading session, ANNX stock reached the peak price of $7.18 while $2.03 was the lowest point it dropped to. The percentage change in ANNX stock occurred in the recent session was 12.29% while the dollar amount for the price change in ANNX stock was $0.68.
-
ANNX's industry and sector of operation?
-
The NASDAQ listed ANNX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ANNX?
-
Ted Yednock | Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board
Jennifer Lew | Executive Vice President, Chief Financial Officer & Corporate Secretary
Shikhar Agarwal | Senior Vice President & Head of Commercial
Michael Overdorf | Executive Vice President & Chief Business Officer
Douglas Love | Chief Executive Officer, President & Director -
How many employees does ANNX have?
-
Number of ANNX employees currently stands at 96. ANNX operates from 1400 Sierra Point Parkway, Brisbane, CA 94005, US.
-
Link for ANNX official website?
-
Official Website of ANNX is: https://www.annexonbio.com
-
How do I contact ANNX?
-
ANNX could be contacted at phone #650 822 5500 and can also be accessed through its website. ANNX operates from 1400 Sierra Point Parkway, Brisbane, CA 94005, US.
-
How many shares of ANNX are traded daily?
-
The average number of ANNX shares traded daily for last 3 months was 3.2M.
-
What is the market cap of ANNX currently?
-
The market value of ANNX currently stands at $745.32M with its latest stock price at $6.232